Pay in 4 interest-free payments of $5.23 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Verified data helps patients see progress they would otherwise miss reframing the plateau as a normal, expected stage
doi:10.3803/EnM.2024.1942 Lilly Investor Relations, News Release: Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine, May 11, 2025
This design allows for easy and controlled application of the cream on the skin
As semaglutide suppresses appetite and delays gastric emptying, patients do not feel an urge to eat frequently, which helps with weight loss and weight management
Related topic hubs Compare Head-to-head comparisons GLP-1 Guide How the class works Retatrutide The headline drug Drug profile pages Each drug has a dedicated profile page mechanism, trials, every comparison involving it, and safety context in one place
